Full-Time

VP – Regulatory Affairs

Confirmed live in the last 24 hours

BridgeBio

BridgeBio

501-1,000 employees

Develops medicines for genetic diseases

Biotechnology

Compensation Overview

$305k - $365kAnnually

+ Performance Bonus + Equity

Expert

San Francisco, CA, USA

Hybrid position based in San Francisco, CA.

Category
Risk & Compliance
Legal & Compliance
Requirements
  • Bachelor's degree in scientific field required. Advanced degree (MD, PhD, PharmD, MS) preferred
  • A minimum of 15 years of relevant pharmaceutical/biotechnology regulatory affairs experience in the pharmaceutical industry, including experience leading a Regulatory Affairs group
  • Well versed in drug development process and regulatory requirements, as well as a good understanding of the underlying science
  • Strong attention to detail
  • Excellent written and verbal communication skills
  • Excellent project management skills, with ability to manage multiple projects and prioritize appropriately
  • Ability to rapidly understand & analyze complex problems/situations
  • Ability to lead teams under tight timelines and be willing to contribute significantly to day-to-day operations as needed
  • Comfort in a team environment
  • Strong interpersonal skills and the ability to effectively work with others.
  • Ability to influence without authority, lead change
  • Ability to solicit information, persuade others, and shape outcomes.
  • Experience working with all levels of management and consulting with key business stakeholders (internal and external)
Responsibilities
  • Provide leadership in creating and executing proactive regulatory strategies for product development, approval and registration
  • Apply knowledge of global quality/regulatory standards and guidelines to ensure requirements are met across programs
  • Partner with internal senior leadership to align closely on cross-functional global regulatory plans and company’s short and long-term strategic objectives
  • Take full ownership of relevant regulatory submission deliverables
  • Provide leadership and oversight of the preparation of all critical global regulatory submissions (from pre-IND to post-marketing) to the FDA, EMA, and other global health authorities
  • Represent regulatory in senior management discussions and present strategies, recommendations, and risks accordingly
  • Work at both high-level strategic and hands-on in leading a nimble team

BridgeBio Pharma develops medicines specifically for genetic diseases, focusing on conditions with well-understood genetic causes. The company uses a decentralized subsidiary model, allowing each subsidiary to concentrate on specific therapies while sharing central resources. This structure enhances efficiency and enables the advancement of multiple drug programs at once. BridgeBio utilizes advancements in genome sequencing and molecular biology to identify and develop effective treatments. Their goal is to create significant therapeutic improvements by targeting diseases at their genetic source. With over 15 drug programs aimed at 20 different genetic diseases, BridgeBio aims to bring treatments to market more quickly than traditional biopharma processes. The company promotes a culture of independent thinking and transparency, which supports rapid, data-driven decision-making.

Company Stage

IPO

Total Funding

$704.4M

Headquarters

Palo Alto, California

Founded

2014

Growth & Insights
Headcount

6 month growth

20%

1 year growth

52%

2 year growth

101%
Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with PANTHERx Rare ensures strategic patient access to therapies.
  • Recent investments indicate strong financial backing and confidence in BridgeBio.
  • Launch of BridgeBio Oncology Therapeutics expands into precision oncology with $200m funding.

What critics are saying

  • Alnylam's Amvuttra poses competitive pressure on BridgeBio's Attruby.
  • KRAS inhibitors face significant scientific and clinical hurdles.
  • Decentralized model may challenge cohesive strategic direction and resource allocation.

What makes BridgeBio unique

  • BridgeBio employs a decentralized subsidiary model for rapid drug development.
  • Focus on genetic diseases with well-understood causes allows targeted therapeutic interventions.
  • Innovative use of genome sequencing and molecular biology for personalized medicine.

Help us improve and share your feedback! Did you find this helpful?